Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 12/20 | 0.40 |
| ▸ | THRA | P10827 | 11/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722484 | 0.91 | ALDH1A1 (0.36) | THRBTHRABRD4KDM4EMEN1 | |
| SCHEMBL5108039 | 0.90 | THRB (0.41) | THRBTHRABRD4 | |
| SCHEMBL5104946 | 0.90 | THRB (0.48) | THRBTHRABRD4 | |
| SCHEMBL5118625 | 0.89 | THRA (0.41) | THRBTHRABRD4 | |
| SCHEMBL5115648 | 0.89 | THRB (0.53) | THRBTHRACA2MEN1KMT2A | |
| SCHEMBL5116438 | 0.89 | THRB (0.51) | THRBTHRAKDM4ECA2MEN1 | |
| SCHEMBL4929450 | 0.89 | THRB (0.41) | THRBTHRACA2MEN1KMT2A | |
| SCHEMBL4926650 | 0.87 | THRB (0.40) | THRBTHRACA2MEN1KMT2A | |
| SCHEMBL4929682 | 0.86 | THRB (0.41) | THRBTHRACA2MEN1KMT2A | |
| SCHEMBL5108841 | 0.86 | FABP4 (0.42) | THRBTHRABRD4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885BRD4 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.